Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Anus Neoplasms 1

Interventions

pembrolizumab 5tislelizumab 2spartalizumab 2Trastuzumab 2Psychiatric Rehabilitation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-12 Subunit p35 2Erlotinib Hydrochloride 2Biopsy 2trastuzumab deruxtecan 1tipifarnib 1regorafenib 1prexasertib 1niraparib 1fludarabine 1enzalutamide 1entinostat 1abiraterone 1Vorinostat 1Thalidomide 1Taxes 1Surveys and Questionnaires 1Specimen Handling 1Ritonavir 1Radiotherapy 1Radionuclide Imaging 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × prexasertib × Thoracic × Clear all
NCT01115790 2016-05-10

A Phase 1 Study in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
150 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡